Click it and Unblock the Notifications
Latest Updates
-
Karwa Chauth Solah Shringar: The Significance Of The 16 Traditional Adornments -
Weight-Loss Injections Are Not a Quick Fix: The Hidden Risks of GLP-1 Drugs -
When Two Epilepsy Medicines Fail, What Should Families Do Next? -
Delhi-NCR Under GRAP 1: The Curbs, the Bans and the Rules to Know -
Sepsis Can Look Like ‘Just a Bad Infection’: Expert Lists Warning Signs Families Need to Know -
Amitabh Bachchan Social Media Break: Doctors Ask Big B To Rest -
Throwback Thursday: Yash Chopra’s Heroines And The Fashion That Defined Bollywood Romance -
Deepika Padukone Wears ₹90,000 Gold Kurta Set As Ranveer Singh, Daughter Dua Twin For Baby Devi’s Name Reveal -
Women, Menopause And Bone Health: Doctor Explains Why Osteoporosis Risk Rises After 40 -
Can Breast Cancer Be Detected Before Symptoms Appear? A Doctor Explains The Role Of Screening
Ebola Vaccine Found Safe In Humans Trials
Ebola vaccine has been recently found to be safe in human trials. Read to know.
An Ebola vaccine has been found to be safe and effective for children and adults in a clinical trial, producing an immune response against the deadly disease, say scientists including one of Indian origin. The worst Ebola virus disease outbreak in history ended in 2016 after infecting 28,600 people and killing about 11,300 worldwide.
It led to urgent action by medical experts across the world to combat this devastating disease; including the setting up of trials of vaccines to stop the disease taking hold. This global commitment to develop a vaccine against the disease suggested eight options, out of a starting pool of 15 candidates, should be evaluated in clinical trials worldwide by the end of 2015.
"An unprecedented Ebola outbreak showed how it is possible for academics, non-governmental organisations, industry and funders to work effectively together very quickly in times of medical crisis," said Sanjeev Krishna, of St George's University of London in the UK. "The results of the trial show how a vaccine could best be used to tackle this terrible disease effectively,"
Krishna said. Considering the persistent replication of the vaccine in children and adolescents, further studies investigating lower doses in this population are warranted. The vaccine contains a non-infectious portion of a gene from the Zaire Ebola virus. In addition, lower vaccine doses should be considered when boosting individuals with pre-existing antibodies to Ebola virus glycoprotein, a finding that has emerged after the vaccine was tested in a country that has experienced Ebolavirus outbreaks in the past.
The vaccine was one of two being examined as a 'candidate' option by the World Health Organization (WHO) to identify urgently a vaccine to combat the Ebola virus outbreak in West Africa.
Disclaimer: The information provided in this article is for general informational and educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified healthcare provider with any questions you may have regarding a medical condition.
Continue with Google
